Acurx Pharmaceuticals (NASDAQ:ACXP) Announces Earnings Results

Acurx Pharmaceuticals (NASDAQ:ACXP) posted its quarterly earnings data on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.15), FiscalAI reports.

Acurx Pharmaceuticals Stock Down 5.7%

ACXP stock traded down $0.09 during midday trading on Friday, hitting $1.40. The company’s stock had a trading volume of 605,747 shares, compared to its average volume of 1,307,159. The stock’s 50-day moving average price is $1.52 and its 200 day moving average price is $2.21. Acurx Pharmaceuticals has a 1 year low of $1.31 and a 1 year high of $8.34. The stock has a market cap of $6.00 million, a price-to-earnings ratio of -0.34 and a beta of -2.03.

Institutional Investors Weigh In On Acurx Pharmaceuticals

Several large investors have recently made changes to their positions in ACXP. Millennium Management LLC purchased a new position in shares of Acurx Pharmaceuticals in the 4th quarter worth about $103,000. Armistice Capital LLC purchased a new stake in Acurx Pharmaceuticals during the second quarter worth about $551,000. Geode Capital Management LLC purchased a new stake in Acurx Pharmaceuticals during the fourth quarter worth about $31,000. Finally, Jane Street Group LLC bought a new stake in Acurx Pharmaceuticals in the fourth quarter worth about $27,000. 11.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ACXP has been the subject of several analyst reports. Wall Street Zen raised shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $31.00.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).